Phase 1 Dose-Escalation Trial Evaluating a Group 2 Influenza Hemagglutinin Stabilized Stem Nanoparticle Vaccine
Joseph P. Casazza,Amelia R. Hofstetter,Pamela J. M. Costner,LaSonji A. Holman,Cynthia S. Hendel,Alicia T. Widge,Richard L. Wu,William R. Whalen, Jennifer Cunningham, Anita Arthur, Xiaolin Wang, Abidemi Ola,Jamie Saunders,Floreliz Mendoza,Laura Novik, Maria C. Burgos Florez,Ana M. Ortega-Villa, Preeti J. Apte,Larisa Strom, Lu Wang, Marjaan Imam,Manjula Basappa,Mursal Naisan,Mike Castro,Jessica F. Trost,Sandeep R. Narpala,Hillary A. Vanderven,Galina V. Yamshchikov,Nina M. Berkowitz,Ingelise J. Gordon,Sarah H. Plummer,Diane L. Wycuff,Sandra Vazquez,Rebecca A. Gillespie,Adrian Creanga,William C. Adams,Kevin Carlton,Jason G. Gall,Adrian B. Mcdermott,Leonid A. Serebryannyy,Katherine V. Houser,Richard A. Koup,Barney S. Graham,Julie E. Ledgerwood,John R. Mascola,Theodore C. Pierson,Sarah F. Andrews,Masaru Kanekiyo,Lesia K. Dropulic NPJ VACCINES（2024）
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper